Intensive chemotherapy for Hodgkin's disease: long-term complications.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions; D005069:Evaluation Studies as Topic; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage / Q000627:therapeutic use; D009369:Neoplasms / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011344:Procarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D011344:Procarbazine; D013739:Testosterone; D008466:Mechlorethamine; D014750:Vincristine; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D011241:Prednisone